How is Omacetaxine dosed?
The appropriate dosage of omacetaxine subcutaneous route should be determined by a doctor.
What is the dosage form of Omacetaxine?
The dosage form of omacetaxine subcutaneous route is Powder for Solution.
How is Omacetaxine administered?
Omacetaxine subcutaneous route is administered through an injection under the skin. It should be given by a healthcare professional in a clinical setting.
What are common precautions when taking Omacetaxine?
Common precautions when taking omacetaxine subcutaneous route include:
- Allergies: Inform your doctor if you have had any unusual or allergic reactions to this medicine or any other medicines.
- Pediatric Use: Safety and efficacy have not been established in the pediatric population. Consult your doctor for further guidance.
- Geriatric Use: Appropriate studies have not demonstrated geriatric-specific problems that would limit the usefulness of omacetaxine injection in the elderly.
- Breastfeeding: There are no adequate studies in women for determining infant risk when using this medication during breastfeeding. Consult your doctor before taking this medication while breastfeeding.
- Drug Interactions: Inform your healthcare professional about all other prescription or nonprescription medications you are taking, as interactions may occur.
- Direct Supervision: This medicine is to be given only by or under the direct supervision of a doctor.
- Side Effects: Be aware of possible side effects, including decreased appetite, depression, double vision, dry skin, ear pain, eye discharge or excessive tearing, eye pain, general feeling of discomfort or illness, hearing loss, heartburn, increased sweating, indigestion, itching skin, muscle spasm, stiffness, or weakness, redness and swelling of the gums, redness, pain, swelling of the eye, eyelid, or inner lining of the eyelid, stomach discomfort or upset, stuffy nose, and others. If you notice any other effects, consult your doctor.
Follow your doctor's instructions carefully and report any side effects to them.